SB 351 – OklahomaStatus: In Process
Year Introduced: 2021
SB 351 requires a practitioner to offer to administer a pharmacogenomic test to a patient prior to
the prescription of any psychotropic drug. The practitioner is required by the measure to inform
the patient that pharmacogenomic tests have not been approved by the Food and Drug Administration. The practitioner must obtain the patient’s informed consent prior to ordering a
pharmacogenomic test and shall provide an estimate to the patient if the practitioner is aware of the cost.
Return to Database Search
© 2018-2019 The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.